CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

This pharma company stock went 8 per cent high, do you own it?
Kiran Shroff
/ Categories: Trending, Mindshare

This pharma company stock went 8 per cent high, do you own it?

With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Lupine Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India. It is one of the world's largest generic drug companies by revenue, globally. The company's areas of focus include medicines for asthma, anti-tuberculosis, etc.  

The quarterly consolidated financial results reveal that the operating profit for Q2FY23 was Rs 467.93 crore compared to a loss of Rs 1251.04 crore for Q2FY22. Net sales for Q2FY23 stood at Rs 4145.52 crore, recording a growth of 1.32 per cent compared to Rs 4091.33 crore in the same quarter last year. The company recorded a net profit of Rs 134.47 crore in the second quarter of FY2023 and posted a loss of Rs.209.489 crore in the second quarter of FY2022.   

On an annual consolidated financial result, the company reported a positive performance on net sales with Rs 16,405.48 crore for FY22, zooming 8.18 per cent from the previous year's value of Rs 15,162.96 crore. The operating profit reached Rs 428.91 crore for FY22 compared to Rs 906.56 crore for FY21, which has decreased by 84.13 per cent. The net loss is Rs 1509.72 crore for FY22 compared to a net profit of Rs 1226.60 crore for FY21.  

Lupin Limited is one of the top 10 pharmaceutical companies. Several environmental projects are planned for the rooftop 1500 KW in Nagpur and 400 KW in Ankleshwar by FY2023. The company also sent 60 per cent of the hazardous waste it generated to co-processing to cement plants. The company received USFDA tentative approval for doxycycline capsules and launched six brands in multiple therapies during the quarter.                                                                                                                      Today at 3:30 pm, at market close, the stock was up by 4.14 per cent to Rs 723. Investors should keep a close eye on this one.  

Previous Article Fundamental Analysis
Next Article Review
Print
1376 Rate this article:
5.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR